Get started

Covidtest

ALNOV Novacyt Graham Mullis, Group CEO of Novacyt, commented: “Novacyt is continuing to address COVID-19 testing for both current and future demand. We continue to ensure that innovation is at the centre of our strategy and that our growing portfolio of COVID-19 tests are available to customers in both private and public health settings to expand existing, and support new, partnerships. Throughout the pandemic, NHS testing demand has remained a key priority for the Company and the contract award under the PHE National Microbiology Framework is a testament to our continued commitment. “We believe our long-term strategy also supports the growth of Novacyt post-COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the COVID-19 testing opportunity but also ensure we are well placed, with both technologies and partners, for sustainable growth beyond COVID-19. We therefore believe Novacyt is well positioned to continue to build on its business transformation.” This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. About Novacyt Group The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
EURONEXT:ALNOVLong
by wallstreetstocks
CEMI Chembio Diagnostics upside potentialChembio Diagnostics' analysts are forecasting revenues of US$54m in 2021, a substantial 56% improvement in sales compared to the last year. CEMI follows its bigger more profitable brother CODX in price action. Depending on the future development of the global pandemic, those stocks could grow rapidly. On 12/3/2020 Craig Hallum brokerage Upgraded the stock from Hold to Buy from $5.00 to $10.00 price target. Because of the offering, I've lowered my price target to 5.5usd. I`m looking forward to read your opinion about CEMI.
CLong
by TopgOptions
CEMI Chembio Diagnostics Earnings August 5thTomorrow Chembio Diagnostics CEMI will Report Second Quarter 2021 Financial Results. Things to consider: $28.3 million purchase order from Bio-Manguinhos for SARS-CoV-2 Antigen tests in Brazil $4 million purchase order from the Partnership for Supply Chain Management (PFSCM), for the purchase of HIV 1/2 STAT-PAK Assay for shipment to Ethiopia those are just some big orders from July, Q3, for which we could se a business update tomorrow at the earnings call. Craig Hallum has a $10.00 price target for it.
CLong
by TopgOptions
2
CODX Co Diagnostics SellOff. Buy oportunity?If you missed the 2x from my previews call: Then you should know that the stock was hit by a big selloff, even though they beat the consensus analyst revenue estimate in Q4 with sales being higher 24% year over year to $27.1 million. This might be your 50% upside potential chance. If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:CODXLong
by TopgOptions
4
XSPA Our patience is running out and ready for a break outFor the past 24 trading days the RSI has been trading in the 20-30 range and yesterday (9/28) is the first day it reached slightly above 40 signaling more confidence than it has in the last month. The volume traded today, Sept. 29 (2.1 million, RSI 41.51) was 3 million less than the day before, Sept. 28 (5.1 million, RSI 44.51) which I am going to assume the bulls shook out the last of the bears. The Bollinger Bands are coming to a squeeze after bouncing around for the whole month of September trading in a tunnel between $1.66-2.12. XSPA needs news... bad. Were tonight's debates about a vaccine enough to push this back above its 50 day trading average of 2.79? XSPA needs GREAT news to push this up 47% so it can begin trading above the 50 DMA, as it has been since August 6 since the last time it traded above the 50 DMA. Current support of 1.66 used to be resistance prior to the news of XSPA contract signing with JFK airport on May 22. The breakout from a bullish flag often results in a powerful move higher, usually measuring the length of the prior flag pole but first this must past resistance (R2) of 2.12. Once this has been achieved, (R3) 3.74, and (R4) 4.74 should soon follow. It is inevitable that business is picking up, people need to travel for work, people WANT a vacation AWAY from home, and airports will forever be accused of being a breeding ground for sickness and disease. There is NO reason XSPA's COVID testing/wellness concept at airports will fail unless it fails internally. Yes, I am a bag holder for now, but you cannot lose if you do not sell. I believe this is a long hold at least until after the election which brings us to holiday travel. If XSPA is operational at all major airports for holiday travelers, just maybe it can break its 52 week high of 8.82
XLong
by VelvetBarbie
BIOC Trying To Fill Gap But Can It This Time?Looks like Biocept BIOC is making another technical move on more information from the company's website about its COVID testing. Apparently people on social are talking about updates that the company is doing COVID testing now. Company site specifically stating: "To support public health efforts, Biocept is performing COVID-19 testing. If you’re in need of testing, please consult with your doctor or authorized healthcare provider as Biocept will need them to order and collect the specimen for COVID-19 testing, per FDA guidance." It's interesting that this is being pointed out. I looked at WayBackMachine and see some updates but nothing that drastic. Either way, it seems like it was enough to get the juices flowing for some people on twitter. Guess we'll see what happens next. Chart has been riding the same support and testing the upper end of that previous gap. Who's placing bets on the over (going up) or the under (coming back down)?
B
by PennyStocks101